Mary Gates
Publications by Year
Research Areas
Estrogen and related hormone effects, Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, DNA Repair Mechanisms
Most-Cited Works
- → Kainate receptors are involved in synaptic plasticity(1999)323 cited
- → LY503430, a Novel α-Amino-3-hydroxy-5-methylisoxazole-4-propionic Acid Receptor Potentiator with Functional, Neuroprotective and Neurotrophic Effects in Rodent Models of Parkinson’s Disease(2003)105 cited
- → Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors(2019)88 cited
- → Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro(2001)78 cited
- → Biarylpropylsulfonamides as Novel, Potent Potentiators of 2-Amino-3- (5-methyl-3-hydroxyisoxazol-4-yl)- propanoic Acid (AMPA) Receptors(2000)75 cited
- → Pharmacological Characterization of the Competitive GLUK5 Receptor Antagonist Decahydroisoquinoline LY466195 in Vitro and in Vivo(2006)74 cited
- → A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer.(2020)56 cited
- → A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors.(2012)48 cited
- → Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans(2015)44 cited
- → Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors.(2011)44 cited